Rhumbline Advisers Sells 14,261 Shares of Stryker Co. (NYSE:SYK)

Rhumbline Advisers cut its holdings in Stryker Co. (NYSE:SYK) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 652,610 shares of the medical technology company’s stock after selling 14,261 shares during the period. Rhumbline Advisers owned 0.17% of Stryker worth $234,972,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SYK. Dunhill Financial LLC increased its position in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Stryker in the third quarter valued at approximately $36,000. Activest Wealth Management acquired a new stake in shares of Stryker in the fourth quarter worth $36,000. Crews Bank & Trust bought a new position in Stryker during the fourth quarter worth $39,000. Finally, Hara Capital LLC acquired a new position in Stryker during the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $385.05 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm’s 50-day moving average price is $377.31 and its two-hundred day moving average price is $366.30. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $146.79 billion, a price-to-earnings ratio of 49.62, a P/E/G ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business posted $3.46 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s dividend payout ratio is 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on SYK shares. Needham & Company LLC restated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Canaccord Genuity Group lifted their target price on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Robert W. Baird upped their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.